Cassava up after dosing completed in controlled Alzheimer's drug trial

Filana Therapeutics

11/05/2023 17:51

** Shares of biotech firm Cassava Sciences Inc  SAVA.O  up
2.7% at $27.8
    ** Co reports dosing completion in a six-month, randomized
controlled trial with 125 patients for late-stage Alzheimer's
disease drug candidate, simufilam 
    ** Simufilam is SAVA's investigational oral drug treatment
for Alzheimer's disease dementia 
    ** Differences that emerge between the group of patients
that continued to take simufilam versus the group of patients
randomized to placebo may suggest evidence of simufilam's
efficacy - Co
    ** Expects to announce top-line data from the six-month
trial in Q3 of 2023
    ** In 2022, simufilam was under fire over allegations that
data on the oral drug was manipulated, but later in the year it
was found that there was no "convincing" evidence to support the
claim
    ** Including session's gain, stock down 6% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))